Leap Therapeutics, Inc. — Q2 2018 Form 10-Q
Filing identity: The supplied filing is for Leap Therapeutics, Inc., not the company named in the request metadata, Cypherpunk Technologies Inc. Confirm the intended issuer before relying on this summary. The filing covers the quarter and six months ended June 30, 2018; financial statements are unaudited.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidates are DKN-01, an antibody targeting DKK1, and TRX518, an antibody targeting GITR. Neither candidate is FDA-approved, and the company reported no product revenue.
Financial results and position
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| R&D expense | $4.234m | $4.881m | $8.465m | $11.285m |
| G&A expense | $2.603m | $2.135m | $4.716m | $5.939m |
| Net loss | $7.364m | $6.905m | $17.986m | $16.319m |
| Net loss per share | $0.50 | $0.74 | $1.32 | $2.03 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $11.531m | $13.411m |
At June 30, cash and cash equivalents were $30.481m, versus $25.737m at year-end 2017. Current assets were $32.048m and current liabilities $6.027m. Total liabilities were $22.272m, including a $16.245m warrant liability; the filing reports no outstanding borrowings at period-end. Stockholders’ equity was $12.135m. Profit margins are not meaningful because the company had no revenue and incurred operating losses.
First-half cash increased by $4.744m: $16.013m of financing inflows offset $11.531m of operating cash use; investing cash flow was zero. Financing included $15.034m net proceeds from the March public offering and $1.217m from warrant exercises.
Material changes versus comparable periods
- Q2 operating expenses declined $0.179m year over year, as R&D fell $0.647m while G&A rose $0.468m. The lower R&D spend reflected timing of manufacturing campaigns, lower CRO and consulting costs; higher G&A reflected legal, audit, consulting and stock-compensation costs.
- Despite lower Q2 operating expenses, net loss increased $0.459m, principally reflecting a $0.662m noncash loss from revaluing warrants and lower Australian R&D incentive income.
- First-half operating expenses decreased $4.043m, but net loss increased $1.667m, mainly because of a $5.513m warrant fair-value loss. Lower expenses largely reflected reduced stock-based compensation versus 2017, which included merger-related awards and charges.
- Common shares outstanding increased to 14,700,681 from 12,354,014 at December 31, 2017, reflecting the public offering and warrant exercises. Potentially dilutive options and warrants were excluded from diluted loss per share as anti-dilutive.
Outlook, commentary and risks
- Management expected available cash and approximately $1.0m in Australian R&D incentive receipts to fund operating expenses for at least 12 months from issuance of the statements. It also planned to seek additional equity, government-program, collaboration or licensing funding. Without additional funding or cost-sharing, trials and R&D could be delayed, reduced or eliminated.
- Management expected R&D spending to increase as development continues, subject to funding, and anticipated higher G&A costs. It could not reliably estimate the timing or cost of completing development or when, if ever, product cash inflows may begin.
- Clinical updates included preliminary responses or disease control in small patient groups in DKN-01 and TRX518 combination studies. These are investigational treatments and early findings; the filing cautions that development and regulatory outcomes are uncertain.
- A collaboration with Pfizer and Merck KGaA was announced to evaluate TRX518 with avelumab and cyclophosphamide; the Phase I/II trial was expected to begin enrolling in Q1 2019. The DKN-01/pembrolizumab study was enrolling expansion cohorts, with full-study enrollment expected during Q1 2019.
- Warrants with full-ratchet anti-dilution provisions are classified as a Level 3 liability and remeasured through earnings; their valuation generated a material, noncash loss. The company had $1.075m of noncancelable manufacturing commitments.
- European patent opposition proceedings affect TRX518-related patents; a hearing on one patent was scheduled for December 2018, and another appeal had no hearing date. The filing reported no material change in previously disclosed risk factors and no material legal proceedings under Item 1, while describing these patent proceedings in the notes.
Important facts for investors to verify
- Confirm issuer identity: the filing is Leap Therapeutics, not Cypherpunk Technologies.
- Check subsequent cash use, financing and the accuracy of the stated 12-month runway assumption.
- Review clinical-trial enrollment, follow-up, response durability and regulatory developments for DKN-01 and TRX518; reported results were preliminary and from small cohorts.
- Assess the warrant terms, Level 3 valuation assumptions, potential dilution and future earnings volatility.
- Track the TRX518 patent opposition outcomes and the company’s ability to meet manufacturing commitments and fund its development plans.